相似文献
1
Focal ablation therapy presents promising results for selectively localized prostate cancer patients.
Chin J Cancer Res. 2023 Aug 30;35(4):424-430. doi: 10.21147/j.issn.1000-9604.2023.04.08.
2
An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years?
Eur Urol. 2022 Jan;81(1):5-33. doi: 10.1016/j.eururo.2021.08.005. Epub 2021 Sep 4.
3
Current evidence for focal therapy and partial gland ablation for organ-confined prostate cancer: systematic review of literature published in the last 2 years.
Curr Opin Urol. 2021 Jan;31(1):49-57. doi: 10.1097/MOU.0000000000000838.
4
New treatments for localized prostate cancer.
Urology. 2008 Dec;72(6 Suppl):S36-43. doi: 10.1016/j.urology.2008.08.506.
5
Focal Minimally Invasive Treatment in Localized Prostate Cancer: Comprehensive Review of Different Possible Strategies.
Cancers (Basel). 2024 Feb 13;16(4):765. doi: 10.3390/cancers16040765.
6
[Laser in prostate cancer. Applicability.].
Arch Esp Urol. 2020 Oct;73(8):724-734.
7
High-intensity focused ultrasound as focal therapy of prostate cancer.
Curr Opin Urol. 2014 May;24(3):225-30. doi: 10.1097/MOU.0000000000000053.
8
Focal therapy in the management of prostate cancer: an emerging approach for localized prostate cancer.
Adv Urol. 2012;2012:391437. doi: 10.1155/2012/391437. Epub 2012 Apr 24.
9
Ablation energies for focal treatment of prostate cancer.
World J Urol. 2019 Mar;37(3):409-418. doi: 10.1007/s00345-018-2364-x. Epub 2018 Jun 25.
10
Focal therapy in prostate cancer: the current situation.
Ecancermedicalscience. 2014 Jun 10;8:435. doi: 10.3332/ecancer.2014.435. eCollection 2014.
引用本文的文献
1
Functional characterization and clinical significance of IGSF8 in pan-cancer: an integrated bioinformatic and experimental study.
Front Immunol. 2025 Aug 27;16:1642193. doi: 10.3389/fimmu.2025.1642193. eCollection 2025.
2
Genetic alterations of prostate cancer: in localized and metastatic prostate cancer.
BMC Urol. 2025 Jul 14;25(1):166. doi: 10.1186/s12894-025-01840-5.
3
Geriatric Nutritional Risk Index (GNRI) and Prognostic Nutritional Index (PNI) Before Treatment as the Predictive Indicators for Bone Metastasis in Prostate Cancer Patients.
Int J Gen Med. 2025 May 24;18:2703-2713. doi: 10.2147/IJGM.S516768. eCollection 2025.
4
MicroRNA-18b-5p Inhibits the Malignant Progression of Prostate Cancer Through Downregulating TRAF5.
Int J Gen Med. 2025 Mar 31;18:1831-1843. doi: 10.2147/IJGM.S494962. eCollection 2025.
5
Exploring the positive association of blood lipid levels with prostate cancer risk and their relationship to pathological features in the Chinese population.
Medicine (Baltimore). 2025 Mar 21;104(12):e41762. doi: 10.1097/MD.0000000000041762.
6
Integrated analysis of single-cell and bulk transcriptomes uncovers clinically relevant molecular subtypes in human prostate cancer.
Chin J Cancer Res. 2025 Jan 30;37(1):90-114. doi: 10.21147/j.issn.1000-9604.2025.01.07.
7
A preliminary follow-up study on irreversible electroporation therapy in older patients with prostate cancer.
Discov Oncol. 2025 Mar 7;16(1):278. doi: 10.1007/s12672-025-02025-0.
8
Tracing the Evolution of Sex Hormones and Receptor-Mediated Immune Microenvironmental Differences in Prostate and Bladder Cancers: From Embryonic Development to Disease.
Adv Sci (Weinh). 2025 Apr;12(13):e2407715. doi: 10.1002/advs.202407715. Epub 2025 Feb 25.
9
Microbiota and urinary tumor immunity: Mechanisms, therapeutic implications, and future perspectives.
Chin J Cancer Res. 2024 Dec 30;36(6):596-615. doi: 10.21147/j.issn.1000-9604.2024.06.03.
10
Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer.
Endocr Relat Cancer. 2025 Jan 10;32(2). doi: 10.1530/ERC-24-0140. Print 2025 Feb 1.
本文引用的文献
1
Mutations in epigenetic regulator detected by liquid biopsy are associated with worse survival in prostate cancer patients.
Oncol Res. 2023 Jun 27;31(4):605-614. doi: 10.32604/or.2023.028321. eCollection 2023.
2
Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective.
Oncol Res. 2023 Jan 12;30(3):137-155. doi: 10.32604/or.2022.026074. eCollection 2022.
3
Melatonin and Prostate Cancer: Anti-tumor Roles and Therapeutic Application.
Aging Dis. 2023 Jun 1;14(3):840-857. doi: 10.14336/AD.2022.1010.
4
Comments on .
Chin J Cancer Res. 2022 Oct 30;34(5):456-457. doi: 10.21147/j.issn.1000-9604.2022.05.05.
5
Focal Therapy of Prostate Cancer Index Lesion With Irreversible Electroporation. A Prospective Study With a Median Follow-up of 3 Years.
J Urol. 2023 Jan;209(1):261-270. doi: 10.1097/JU.0000000000002970. Epub 2022 Sep 8.
6
National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version).
Chin J Cancer Res. 2022 Jun 30;34(3):270-288. doi: 10.21147/j.issn.1000-9604.2022.03.07.
7
Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial.
JAMA Surg. 2022 Aug 1;157(8):693-700. doi: 10.1001/jamasurg.2022.2230.
8
A gene prognostic index from cellular senescence predicting metastasis and radioresistance for prostate cancer.
J Transl Med. 2022 Jun 3;20(1):252. doi: 10.1186/s12967-022-03459-8.
9
PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01).
Int J Radiat Oncol Biol Phys. 2022 Aug 1;113(5):1025-1035. doi: 10.1016/j.ijrobp.2022.04.020. Epub 2022 Apr 22.
10
Energy Metabolism-Related Gene Prognostic Index Predicts Biochemical Recurrence for Patients With Prostate Cancer Undergoing Radical Prostatectomy.
Front Immunol. 2022 Feb 24;13:839362. doi: 10.3389/fimmu.2022.839362. eCollection 2022.
Zotero 插件